Eli Lilly to acquire gene-editing biotech company Verve Therapeutics for $1.3 billion. Here's why

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a potential long-term growth.

Companies